SCHEMBL2800478

SCHEMBL2800478

CCS(=O)(=O)NC(=O)c1cnn2c(Nc3ccccc3Cl)c(C(=O)N3CCC(c4ccccc4)CC3)cnc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT5 Q9NXA8 4/20 0.46
SIRT2 Q8IXJ6 1/20 0.41
EGLN1 Q9GZT9 2/20 0.41
NPC1 O15118 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
USP5 P45974 1/20 0.37
MGLL Q99685 2/20 0.37
HPGD P15428 1/20 0.37
CCKBR P32239 1/20 0.37
SPR P35270 2/20 0.36
TRPC3 Q13507 1/20 0.36
TRPC6 Q9Y210 1/20 0.36
CCR5 P51681 1/20 0.36
FASN P49327 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2801637 0.95 SIRT5 (0.41) SIRT5SIRT2EGLN1NPC1GAA
SCHEMBL2799996 0.93 SIRT5 (0.40) SIRT5SIRT2EGLN1NPC1MAPT
SCHEMBL2801754 0.92 ALDH1A1 (0.42) SIRT5SIRT2EGLN1GAAMAPT
SCHEMBL2801510 0.91 EGLN1 (0.38) SIRT5EGLN1ALDH1A1USP5SPR
SCHEMBL2803213 0.91 NPC1 (0.40) SIRT5NPC1RAB9AALDH1A1SPR
SCHEMBL2801762 0.90 EGLN1 (0.39) SIRT5EGLN1NPC1MAPTRAB9A
SCHEMBL2798787 0.90 TNF (0.36) SIRT5EGLN1ALDH1A1MGLLCCKBR
SCHEMBL2803776 0.90 SPR (0.38) SIRT5SMN1; SMN2ALDH1A1USP5SPR
SCHEMBL2802343 0.90 JAK2 (0.38) SIRT5EGLN1ALDH1A1MGLLCCKBR
SCHEMBL2802383 0.89 HPGD (0.45) GAAMAPTALDH1A1CNR2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 SIRT5 2237/4885SIRT2 1605/4885EGLN1 1967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.